AnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of “Moderate Buy” by Analysts

AnaptysBio, Inc. (NASDAQ:ANAB) has been given a consensus rating of “Moderate Buy” by the ten research firms that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $42.38.

A number of brokerages have weighed in on ANAB. HC Wainwright raised AnaptysBio from a “neutral” rating to a “buy” rating and lifted their target price for the company from $22.00 to $38.00 in a research report on Wednesday, June 4th. Johnson Rice reiterated a “buy” rating on shares of AnaptysBio in a research note on Wednesday, March 26th. JPMorgan Chase & Co. lifted their target price on AnaptysBio from $36.00 to $42.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. Guggenheim reiterated a “buy” rating and issued a $90.00 target price (up previously from $54.00) on shares of AnaptysBio in a research note on Wednesday, May 28th. Finally, Wedbush reiterated an “outperform” rating and issued a $40.00 target price on shares of AnaptysBio in a research note on Thursday, May 29th.

AnaptysBio Stock Down 3.9%

Shares of NASDAQ ANAB opened at $22.47 on Monday. The business has a fifty day simple moving average of $21.67 and a two-hundred day simple moving average of $18.38. The firm has a market cap of $660.17 million, a PE ratio of -4.63 and a beta of -0.26. AnaptysBio has a twelve month low of $12.21 and a twelve month high of $41.31.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Monday, May 5th. The biotechnology company reported ($1.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.30) by $0.02. The business had revenue of $27.77 million during the quarter, compared to analyst estimates of $15.27 million. AnaptysBio had a negative return on equity of 282.47% and a negative net margin of 125.70%. On average, research analysts expect that AnaptysBio will post -6.08 earnings per share for the current year.

AnaptysBio declared that its Board of Directors has authorized a stock buyback program on Monday, March 24th that allows the company to buyback $75.00 million in outstanding shares. This buyback authorization allows the biotechnology company to purchase up to 13.1% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its stake in AnaptysBio by 0.8% during the 4th quarter. Wellington Management Group LLP now owns 66,467 shares of the biotechnology company’s stock worth $880,000 after buying an additional 528 shares during the last quarter. Rhumbline Advisers grew its stake in AnaptysBio by 2.7% during the 1st quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock valued at $574,000 after purchasing an additional 826 shares during the last quarter. Virtus ETF Advisers LLC grew its stake in AnaptysBio by 24.7% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,733 shares of the biotechnology company’s stock valued at $63,000 after purchasing an additional 936 shares during the last quarter. US Bancorp DE grew its stake in AnaptysBio by 126.5% during the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 979 shares during the last quarter. Finally, California State Teachers Retirement System grew its stake in AnaptysBio by 10.3% during the 4th quarter. California State Teachers Retirement System now owns 14,590 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 1,359 shares during the last quarter.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.